Exogenous testosterone therapy and fertility are fundamentally incompatible. In a talk at the 2025 Sexual Medicine Society of North America meeting in Grapevine, Texas, titled “Testosterone and ...
LithoVue Elite system's real-time IRP monitoring may enhance flexible ureteroscopy for larger stones, offering data-driven pressure management. CVAC 2.0 ureteroscope demonstrates safety and efficacy ...
The ProVee Urethral Expander System met safety and effectiveness endpoints in a pivotal phase 3 study, leading to its approval for BPH treatment. Rezūm Water Vapor Therapy received FDA approval for ...
The PROSTOX ultra test predicts late genitourinary toxicity risks in localized prostate cancer patients undergoing stereotactic body radiotherapy. Genomic testing aids in refining treatment intensity ...
The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive ...
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...
Nogapendekin alfa inbakicept combined with BCG shows promise for BCG-unresponsive NMIBC CIS, with a 71% complete response rate in a single-arm trial. The European Medicines Agency's conditional ...
The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
The Zenflow Spring Implant offers a reversible, durable BPH treatment, preserving natural anatomy with a spring-like implant. The BREEZE study showed a 60% responder rate and 37% IPSS improvement, ...
Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...
The ProVee System received FDA approval for treating BPH, offering a safe and effective procedure for symptom relief and quality of life improvement. The ProVIDE study showed significant improvement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback